Format

Send to

Choose Destination
J Infect Dis. 2015 Jul 15;212(2):258-63. doi: 10.1093/infdis/jiv022. Epub 2015 Jan 13.

Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir.

Author information

1
Department of Medicine.
2
Department of Molecular Virology and Microbiology, Department of Immunology, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas.
3
Department of Cellular Therapy, Children's National Medical Center, Washington, District of Columbia.
4
Department of Medicine Department of Microbiology and Immunology Department of Epidemiology, University of North Carolina Chapel Hill, Chapel Hill.

Abstract

Enhanced human immunodeficiency virus (HIV)-specific immunity may be required for HIV eradication. Administration of autologous, ex vivo expanded, virus-specific, cytotoxic T-lymphocytes derived from HIV-infected patients on suppressive antiretroviral therapy (HXTCs) are a powerful tool for proof-of-concept studies. Broadly specific, polyclonal HXTCs resulting from ex vivo expansion demonstrated improved control of autologous reservoir virus compared to bulk CD8(+) T cells in viral inhibition assays. Furthermore, patient-derived HXTCs were able to clear latently infected autologous resting CD4(+) T cells following exposure to the latency-reversing agent, vorinostat. HXTCs will be ideal reagents to administer with precise control in future in vivo studies in combination with latency-reversing agents.

KEYWORDS:

HIV T cells; HIV cure; HIV eradication; HIV immunology; adoptive T-cell therapy; ex vivo expanded T cells; latent reservoir; vorinostat

PMID:
25589335
PMCID:
PMC4490234
DOI:
10.1093/infdis/jiv022
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center